Exhibit 99.1

             PharmaFrontiers Completes $5.08 MM Financing

   THE WOODLANDS, Texas--(BUSINESS WIRE)--June 20, 2005--
PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the
development and commercialization of cell therapies, has completed a
private placement to institutional and other accredited investors of
approximately 3,387,217 units at $1.50 per unit; each unit is
comprised of one share of newly issued common stock and three separate
types of warrants to purchase a total of 2.75 shares of common stock
at stated exercise prices for each type of warrant. Aggregate gross
proceeds to the Company were $5.08MM. In connection with the private
placement, PharmaFrontiers has agreed to file a registration statement
on Form SB-2 by July 15, 2005 to register the re-sale of the shares of
common stock and the shares underlying the warrants.

   About PharmaFrontiers Corp.

   PharmaFrontiers' strategy is to develop and commercialize cell
therapies to treat several major disease areas such as cardiac and
pancreatic conditions and Multiple Sclerosis. The company holds the
exclusive worldwide license from the University of Chicago through its
prime contractor relationship with Argonne National Laboratory for
patents relating to the use of adult pluripotent stem cells derived
from patients' own circulating blood. PharmaFrontiers also owns
patented and proprietary individualized cell therapies that are in FDA
Phase I/II human dose ranging clinical trials to evaluate their safety
and effectiveness in treating MS.

   Safe Harbor Statement

   This press release contains "forward-looking statements,"
including statements about PharmaFrontiers' growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that are
not historical facts or information. These forward-looking statements
are based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors, specifically
including those relating to PharmaFrontiers' ability to obtain
additional funding, develop its stem cell technologies, achieve its
operational objectives, and obtain patent protection for its
discoveries, that may cause PharmaFrontiers' actual results to be
materially different from any future results expressed or implied by
such forward-looking statements. PharmaFrontiers undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.

    CONTACT: PharmaFrontiers Corp.
             C. William Rouse, 281-775-0608
             brouse@pharmafrontierscorp.com
                 or
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777 (Investor Relations)
             kgolodetz@lhai.com
             Bruce Voss, 310-691-7100 (Investor Relations)
             bvoss@lhai.com